Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib + Chemotherapy in Newly Diagnosed Multimetastatic Ewing Sarcoma
NCT05830084Phase 1Active, not recruiting
- Sponsor
- Gustave Roussy
- Start
- Jun 2023
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label, single-arm trial of regorafenib in Ewing sarcoma, sponsored by Gustave Roussy. Primary endpoint: Dose-Limiting Toxicities at 28 days. Started Jun 2023; status: active, not recruiting.
02
Drugs
regorafenib
03
Conditions
Ewing sarcoma
Beyond the preview
Go deeper on NCT05830084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05830084.